Name: Responsive Respiratory 3 Cylinder CarMate D, E Carrier,CarMate D, E Carrier,Each,150-0113
Brand: RESPONSIVE RESPIRATORY INC
SKU: 1187866363
Price: 43.99 USD
Availability: InStock

Responsive Respiratory 3 Cylinder CarMate D, E Carrier,CarMate D, E Carrier,Each,150-0113 - 1187866363

By RESPONSIVE RESPIRATORY INC

$43.99

(771 Reviews)

Model

1187866363

Store

Health Products For You
Premium Online Retailer Of Health Products, Medical Supplies & HomeCare Medical Equipments. Healthcare & Healthy Living Store. Affordable Healthcare Essentials.

Manufacturer

RESPONSIVE RESPIRATORY INC

Detail

Responsive Respiratory 3 Cylinder CarMate D, E Carrier is the patient cylinder transport solution. It restrains oxygen cylinders for safe vehicle transport and gets installed easily into rear seats using built-in latch tether system (all cars built after 2003 have integrated hook in the rear seat crease to attach car seats - CarMate uses these hooks). Highlights of Cylinder CarrierResponsive Respiratory 3 Cylinder CarMate D, E Carrier provides quiet, rattle free transportCompartmentalized design holds three cylindersEasy open/close clips secure cylinders quickly into carrier

Category

Respiratory

Background In two pivotal phase 3 trials, up to 24 weeks of treatment with elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) was efficacious and safe in patients with cystic fibrosis (CF) ≥12 years of age who have at least one F508del allele. The aim of this study is to assess long-term safety and efficacy of ELX/TEZ/IVA in these patients. Methods In this phase 3, open-label, single-arm extension study, participants with F508del –minimal function (from a 24-week parent study; n=399) or F508del – F508del (from a 4-week parent study; n=107) genotypes receive ELX/TEZ/IVA at the same dose (ELX 200 mg once daily, TEZ 100 mg once daily and IVA 150 mg every 12 h). The primary end-point is safety and tolerability. A prespecified interim analysis was conducted when the last participant reached the Week 144 visit. Results At the Week 144 in...

>Read More

Background Hypoxic burden (HB) has emerged as a strong predictor of cardiovascular risk in obstructive sleep apnoea (OSA). We aimed to assess the potential of HB to predict the cardiovascular benefit of treating OSA with continuous positive airway pressure (CPAP). Methods This was a post hoc analysis of the ISAACC trial ( ClinicalTrials.gov : NCT01335087) including non-sleepy patients with acute coronary syndrome (ACS) diagnosed with OSA (apnoea–hypopnoea index ≥15 events·h –1 ) by respiratory polygraphy. Patients were randomised to CPAP or usual care and followed for a minimum of 1 year. HB was calculated as the total area under all automatically identified desaturations divided by total sleep time. Patients were categorised as having high or low baseline HB according to the median value (73.1%min·h –1 ). Multivariable Cox regression...

>Read More

Extract Obstructive sleep apnoea (OSA) is the most common form of sleep disordered breathing, affecting nearly one billion middle-aged individuals worldwide [1]. OSA is extensively accepted as a significant risk factor for a variety of cardiovascular diseases, including hypertension, coronary heart disease, stroke and arrhythmias [2]. First-line, gold-standard therapy for moderate-to-severe OSA is continuous positive airway pressure (CPAP), which secures the upper airway during sleep, eliminates apnoeas and hypopnoeas and restores sleep architecture [3]. One of the major unresolved questions in the field of sleep apnoea is whether treatment with CPAP prevents incidents cardiovascular events and mortality. The hypothesis underlying three pivotal randomised controlled trials (RCTs) (SAVE, ISAACC and RICCADSA) was to consider sleep apnoea as an independent cardiovascular risk factor. A r...

>Read More

Extract Since the discovery of the cystic fibrosis transmembrane conductance regulator ( CFTR ) gene in 1989, greater understanding of gene variants and their functional consequences have raised the ambition of treating the underlying cause of cystic fibrosis (CF) and thereby changing the disease trajectory of this life-limiting progressive condition [1]. Recent successful efforts have targeted the dysfunctional protein product formed as a result of gene variants in an effort to improve its function. In a landmark trial, a novel compound, ivacaftor, increased protein function for a subset of individuals with a specific CFTR gene variant as measured by the biomarker sweat chloride [2]. This improvement translated to meaningful clinical benefits in terms of lung function, the frequency of pulmonary exacerbations and nutritional status [2]. Approximately 5% of people with CF were carri...

>Read More

Product Details for 1187866363